Project description DEENESFRITPL Ground-breaking effort to treat diabetic foot ulcers Diabetic foot ulcers (DFUs) are a significant complication of diabetes that has proven to be an unmet clinical condition. DFUs can lead to hospitalisation, limb amputation, and even death, with a high recurrence rate. The EU-funded APTADEGRAD project will provide a potential solution by developing a novel therapy based on aptamer based lysosome-targeting chimaeras (LYTACs) to heal DFUs. The therapy will target key proteins responsible for impaired healing in diabetic wounds, offering a controlled and dose-dependent reduction of MMP-9, IL-1β, and its receptor IL-1R1. If successful, this project could offer a potential treatment for other types of chronic wounds and immune pathologies, with essential knowledge gained about LYTACs for future pharmaceutical development. Show the project objective Hide the project objective Objective Diabetic foot ulcers (DFUs) a major complication of diabetes, occur in ~25% of patients, with a five-year recurrence rate of ~65% . DFUs often end in hospitalization, with limb amputations in up to 60% of cases . DFU related mortality is 5% within twelve months, rising to 42% after five years. Despite high prevalence and its major impact on the quality of life, no effective treatment has been approved, so DFU remain a highly unmet clinical condition.APTADEGRAD aims at obtaining in vivo proof-of-concept for a novel, first-in-class therapy using aptamer-based Lysosome Targeted Chimeras (LYTACs) to heal diabetic foot ulcers (DFUs). These LYTACs will target IL-1β, its receptor IL-1R1, and MMP-9 for degradation, proteins known to play a key role in impaired healing in diabetic wounds. Out hypothesis is that a) aptamer-based LYTACs MoA, may offer the potential to deliver a controlled, dose-dependent reduction of MMP9, IL-1b and its receptor IL-1R1, moderating the excessive DFU inflammatory response, while maintaining biologically beneficial levels of these proteins to promote healing and prevent infection; b) the simultaneous targeting of these relevant proteins will produce a synergetic effect in the inflammation cascade, providing superior efficacy outcomes.Should the main objective of the project is achieved (i.e. show efficacy in animal models of DFU), we would be showing for the first time a potential therapy based on LYTACs, in this case in the context of diabetic ulcers, with potential applications in other types of chronic wound or immune pathologies. In addition to efficacy data, we will be gathering essential knowledge about LYTACs (toxicity, efficacy, mechanism of action, differences with other approaches such as blocking or inhibition which are essential for successful future translation of the novel concept of LYTAC in pharmaceutical development to clinical trials. Fields of science social sciencessociologydemographymortalitynatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesbasic medicinepathology Programme(s) HORIZON.3.1 - The European Innovation Council (EIC) Main Programme Topic(s) HORIZON-EIC-2022-PATHFINDEROPEN-01-01 - EIC Pathfinder Open 2022 Call for proposal HORIZON-EIC-2022-PATHFINDEROPEN-01 See other projects for this call Funding Scheme EIC - EIC Coordinator LINCBIOTECH SOCIEDAD LIMITADA Net EU contribution € 714 375,00 Address PQUE TECNOLOXICO DE GALICIA - EDIFICIO TECNOPOLE I O DAS VINAS 32980 OURENSE Spain See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Noroeste Galicia Ourense Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 714 375,00 Participants (3) Sort alphabetically Sort by Net EU contribution Expand all Collapse all UNIVERSIDADE DO MINHO Portugal Net EU contribution € 600 530,00 Address LARGO DO PACO 4704 553 Braga See on map Region Continente Norte Cávado Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 600 530,00 SYNABS Belgium Net EU contribution € 602 288,75 Address RUE AUGUSTE PICCARD 48 6041 Charleroi See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Région wallonne Prov. Hainaut Arr. Charleroi Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 602 288,75 SERVIZO GALEGO DE SAUDE Spain Net EU contribution € 404 483,75 Address Edificio Administrativo San Lázaro 15703 Santiago De Compostela See on map Region Noroeste Galicia A Coruña Activity type Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 404 843,75 Partners (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all UNIVERSITY OF HULL United Kingdom Net EU contribution € 0,00 Address COTTINGHAM ROAD HU6 7RX Hull See on map Region Yorkshire and the Humber East Yorkshire and Northern Lincolnshire Kingston upon Hull, City of Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost No data
